RxDoctor Payments Data

Yasmeen Agha, MD

Family Medicine · San Antonio, TXNPI 1164865762

Payments from drug & device makers

$11,161in general payments, 2019–2025

Across 625 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$820
  • Lilly USA, LLC$747
  • Otsuka America Pharmaceutical, Inc.$581
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$11,06099%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,161 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$307,382
Medicare patients
468
Services billed
4,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$126,716
OzempicSemaglutide105$121,457
MounjaroTirzepatide72$72,795
FarxigaDapagliflozin Propanediol99$68,643
JardianceEmpagliflozin40$54,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$33,780
VraylarCariprazine Hcl30$28,171
RexultiBrexpiprazole20$24,386
XareltoRivaroxaban54$24,221
LinzessLinaclotide22$23,186
RybelsusSemaglutide15$22,036
ProliaDenosumab11$18,656
Tresiba Flextouch U-200Insulin Degludec15$15,333
WegovySemaglutide11$15,298
UbrelvyUbrogepant11$15,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$1,616$158,791131 claims
PfizerEliquis$820$126,716229 claims
Lilly USA, LLCMounjaro, Trulicity$747$87,68188 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,144$78,478115 claims
AbbVieVraylar, Linzess, Ubrelvy, Synthroid$1,372$68,82583 claims
Boehringer IngelheimJardiance$128$54,10440 claims
GSKTrelegy Ellipta$389$33,78044 claims
Otsuka America Pharmaceutical, Inc.Rexulti$581$24,38620 claims
Johnson & JohnsonXarelto$313$24,22154 claims
AmgenProlia$19$18,65611 claims
Astellas Pharma US IncMyrbetriq$277$12,60629 claims
BayerKerendia$391$8,32915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →